Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted

European Journal of Pharmaceutical Sciences

Volumn 22, Issue 5, 2004, Pages 419-425

  Yamanaka, Hiroyuki ^a   Nakajima, Miki ^a   Nishimura, Kiyoko ^a   Yoshida, Ryoko ^a   Fukami, Tatsuki ^a   Katoh, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

CYP2A6; LC MS MS; Nicotine; Poor metabolizer

Indexed keywords

COTININE; CYTOCHROME P450 2A6; DRUG METABOLITE; NICOTINE; NICOTINE GUM;

ADULT; ARTICLE; CHEWING GUM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; EVALUATION; FEMALE; GENE DELETION; GENETIC VARIABILITY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE DELETION; HUMANS; MALE; MIXED FUNCTION OXYGENASES; NICOTINE;

EID: 3242664997     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2004.04.012     Document Type: Article

References (31)

1. Ariyoshi N., Takahashi Y., Miyamoto M., Umetsu Y., Daigo S., Tateishi T., Kobayashi S., Mizorogi Y., Loriot M.A., Stucker I., Beaune P., Kinoshita M., Kamataki T. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics. 10:2000;687-693
2. Ariyoshi N., Sawamura Y., Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem. Biophys. Res. Commun. 281:2001;810-814
3. Ariyoshi N., Sekine H., Saito K., Kamataki T. Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics. 12:2002;501-504
4. Benowitz N.L., Jacob P. III, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin. Pharmacol. Ther. 41:1987;467-473
5. Benowitz N.L. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. N. Engl. J. Med. 319:1988;1318-1330
6. Benowitz N.L., Fong I., Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268:1994;296-303
7. Byrd G.D., Chang K.-M., Greene J.M., deBethizy J.D. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers. Drug Metab. Dispos. 20:1992;192-197
8. Cashman J.R., Park S.B., Yang Z.-C., Wrighton S.A., Jacob P. III, Benowitz N.L. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol. 5:1992;639-646
9. Daigo S., Takahashi Y., Fujieda M., Ariyoshi N., Yamazaki H., Koizumi W., Tanabe S., Saigenji K., Nagayama S., Ikeda K., Nishioka Y., Kamataki T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 12:2002;299-306
10. Kitagawa K., Kunugita N., Kitagawa M., Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem. 276:2001;17830-17835
11. Kuehl G.E., Murphy S.E. N-Glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP- glucuronosyltransferases. Drug Metab. Dispos. 31:2003;1361-1368
12. Kyerematen G.A., Vesell E.S. Metabolism of nicotine. Drug Metab. Rev. 23:1991;3-41
13. Kwon J.T., Nakajima M., Chai S., Yom Y.K., Kim H.K., Yamazaki H., Sohn D.R., Yamamoto T., Kuroiwa Y., Yokoi T. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics. 11:2001;317-323
14. Murphy S.E., Johnson L.M., Pullo D.A. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chem. Res. Toxicol. 12:1999;639-645
15. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996a;1010-1015
16. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Role of human Cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24:1996b;1212-1217
17. Nakajima M., Yamagishi S., Yamamoto H., Yamamoto T., Kuroiwa Y., Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin. Pharmacol. Ther. 67:2000;57-69
18. Nakajima M., Kwon J.T., Tanaka N., Zenta T., Yamamoto Y., Yamamoto H., Yamazaki H., Yamamoto T., Kuroiwa Y., Yokoi T. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther. 69:2001;72-78
19. Nakajima M., Tanaka E., Kwon J.T., Yokoi T. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab. Dispos. 30:2002;1484-1490
20. Nakajima, M., Yoshida, R., Fukami, T., McLeod, H.L., Yokoi, T., 2004. Novel Human CYP2A6 alleles confound gene deletion analysis. FEBS Lett., in press
21. Nunoya K., Yokoi T., Kimura K., Kainuma T., Satoh K., Kinoshita M., Kamataki T. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther. 289:1999a;437-442
22. Nunoya K., Yokoi T., Takahashi K., Kimura K., Kinoshita M., Kamataki T. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metaboliser phenotype. J. Biochem. 126:1999b;402-407
23. Oscarson M., McLellan R.A., Gullsten H., Agundez J.A., Benitez J., Rautio A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Identification and characterization of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett. 460:1999a;321-327
24. Oscarson M., McLellan R.A., Gullsten H., Yue Q.Y., Lang M.A., Bernal M.L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterization and PCR-based detection of CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448:1999b;105-110
25. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284:2001;455-460
26. Tricker A.R. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behavior. Toxicology. 183:2003;151-173
27. Xu C., Rao Y.S., Xu B., Hoffmann E., Jones J., Sellers E.M., Tyndale R.F. An in vivo pilot study characterizing the new CYP2A6*7,*8, and*10 alleles. Biochem. Biophys. Res. Commun. 290:2002;318-324
28. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329
29. Yamazaki H., Inoue K., Hashimoto M., Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol. 73:1999;65-70
30. Yoshida R., Nakajima M., Watanabe Y., Kwon J.K., Yokoi T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol. 54:2002;511-517
31. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J.T., Yokoi T. Effects of polymorphism in promoter region of CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. 74:2003;69-76